Breaking News

Arcturus, ARCALIS Awarded $115M in Grants from the Japanese Government

Will be used to fund the construction of a factory and equipment to support cGMP production of mRNA drug initiatives.

Arcturus Therapeutics Holdings Inc., a global late-stage clinical messenger RNA medicines company, reported that ARCALIS Co., Ltd., its manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, was awarded $115 million in two separate grants from the Japanese government. The grants will be used to fund the construction of a factory and the purchase of capital equipment to support cGMP production of mRNA drug substance and mRNA drug product operations. A...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters